Search results
Showing 7246 to 7260 of 8213 results
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)
This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.
Discontinued Reference number: GID-IP1043
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
Discontinued Reference number: GID-TA10923
Discontinued Reference number: GID-TA11655
In development Reference number: GID-TA11372 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
In development Reference number: GID-TA11367 Expected publication date: TBC